Moreover, the administration of butyrate improved metabolic disorders, including hyperglycemia and hepatic lipogenesis, in a manner mediated by AMPK, GLUT4, and GLP-1 (Gao et al., 2019; Zhang et al., 2019). Here, SLC2A4 is linked to Other metabolic disease.